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Abstract Many of the signaling pathways and regulatory
systems in eukaryotic cells are controlled by proteins with
multiple interaction domains that mediate specific protein^
protein and protein^phospholipid interactions, and thereby
determine the biological output of receptors for external and
intrinsic signals. Here, we discuss the basic features of in-
teraction domains, and suggest that rather simple binary
interactions can be used in sophisticated ways to generate
complex cellular responses. ß 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Interaction domains
The cytoplasmic proteins that convey information from cell
surface receptors to their intracellular targets are commonly
constructed of modular domains, that either have a catalytic
function (such as protein or lipid kinase activity), or mediate
the interactions of proteins with one another, or with phos-
pholipids, nucleic acids or small molecule second messengers
[1]. These latter interaction domains play a critical role in the
selective activation of signaling pathways, through their abil-
ity to recruit target proteins to activated receptors, and to
regulate the subsequent formation of signaling complexes at
appropriate subcellular locations [2,3]. Such interaction do-
mains may control not only the speci¢city of signal transduc-
tion, but also the kinetics with which cells respond to external
and intrinsic cues, as discussed below, and can therefore give
rise to complex cellular behaviors. Interaction domains were
originally identi¢ed in the context of phosphotyrosine signal-
ing, through the ability of Src homology 2 (SH2) domains of
cytoplasmic proteins to recognize speci¢c phosphotyrosine-
containing motifs on activated receptor tyrosine kinases [4^
7]. However, it is now apparent that speci¢c protein^protein
interactions play an essential role in the signaling output of a
wide range of cell surface receptors, as well as in cellular
events such as protein and vesicle tra⁄cking, the cell cycle,
gene expression, DNA repair, control of the cytoskeleton and
targeted protein degradation. Intriguingly, closely related pro-
tein interaction domains are used repeatedly in distinct pro-
teins to mediate a wide range of regulatory processes.
Interaction domains, not surprisingly, appear designed to
recognize exposed features of their binding partners. This ap-
plies to the sizable family of domains and proteins that rec-
ognize post-translationally modi¢ed sequences, including
phosphotyrosine motifs (SH2, phosphotyrosine-binding
(PTB) domains) [4^10], phosphothreonine/serine-containing
elements (i.e. 14-3-3 proteins; FHA, WD40 domains) [11],
acetylated or methylated lysine (bromo and chromo domains)
[12^14] or hydroxyproline motifs (VHL protein) [15,16]. Sim-
ilarly, proline-rich sequences tend to be readily accessible, and
are recognized by interaction modules such as SH3, WW and
EVH1 domains [17^21], the same applies to the extreme C-ter-
mini of proteins, which are frequently bound by PDZ do-
mains [22^25].
In addition to interaction domains that mediate protein^
protein interactions, a growing family of domains bind phos-
pholipids, especially phosphoinositides (PI) (i.e. PH, FYVE,
PX, ENTH, Ferm and Tubby domains) [26,27]. Such modules
bind the lipid’s charged inositol headgroup in a fashion that
depends on its sites of phosphorylation, and are thereby re-
cruited to membrane regions where the relevant phosphoino-
sitides are generated [28,29]. PH domains, for example, tend
to bind PI-4,5-P2 or PI-3,4,5-P3 at the plasma membrane [30^
34], whereas FYVE domains bind PI-3-P in the endosome
compartment [35^38]. As discussed in more detail below, in-
teraction domains can have rather £exible and multivalent
binding properties ; the Tubby domain for example binds
PI-4,5-P2 at the plasma membrane, but also binds DNA fol-
lowing PI-4,5-P2 hydrolysis and consequent translocation of
the Tubby protein to the nucleus [27]. This ability of interac-
tion domains to mediate multiple types of interaction is espe-
cially evident for domains made up of repeated units, notably
TPR repeats, HEAT motifs, ankyrin repeats, leucine-rich re-
peats or WD40 repeats [39^42]. The assembly of these re-
peated elements into larger domains can create quite extensive
binding surfaces with diverse speci¢cities. In addition folded
modular domains can undergo homo- or heterotypic interac-
tions, that result in their dimerization or oligomerization. This
is a notable feature of the domains that regulate apoptotic
signaling cascades (i.e. death domains, death e¡ector domains,
caspase recruitment domains) [43^45], but is also seen for
modules such as SAM domains, which mediate the associa-
tion of a wide range of receptors, cytoplasmic proteins, and
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transcription factors [46^48], and PDZ domains, which can
associate one with another as well as with C-terminal sequen-
ces [49,50].
2. SH2 domains and phosphotyrosine recognition
The ability of interaction domains to mediate the formation
of protein complexes in a fashion that depends on protein
phosphorylation, is typi¢ed by the binding of SH2 domains
to phosphotyrosine sites. SH2 domains are a common feature
of an otherwise diverse group of cytoplasmic polypeptides
(Fig. 1), that serve as intracellular targets of receptor tyrosine
kinases (RTK), and more complex multi-subunit receptors
such as those for antigens, cytokines and extracellular matrix
components [1,51,52]. SH2 domains bind speci¢c phosphoty-
rosine-containing peptide motifs, such as those found in the
non-catalytic region of activated growth factor receptors, lo-
cated either between the membrane and the kinase domain
(juxtamembrane), in a loop inserted into the kinase domain
(kinase insert) or in the C-terminal tail [53]. Such interactions
link receptor autophosphorylation to the activation of speci¢c
cytoplasmic signaling pathways. A signi¢cant fraction of the
binding energy for SH2 domain^phosphopeptide interactions
comes from the association with phosphotyrosine, and the
formation of stable SH2-mediated complexes is therefore
phosphotyrosine-dependent [54,55]. However, a combination
of structural, biochemical and genetic analysis has revealed
that SH2 domains also recognize between three and ¢ve res-
idues immediately C-terminal to the phosphotyrosine, in a
fashion that varies from one SH2 domain to another
[7,54,56^60]. The sequence of residues C-terminal to the phos-
photyrosine of an SH2 domain-binding site can therefore in-
£uence the binding a⁄nity, with ‘optimal’ motifs binding with
approximately 100-fold higher a⁄nity than randomized phos-
phopeptides (although this varies substantially from one SH2
domain to another). The sequence context of an SH2 domain-
binding site can therefore have a signi¢cant e¡ect on the spec-
i¢city with which a given receptor interacts with its down-
stream targets [61,62]. It is important to bear in mind that
the complexes that form in vivo will ultimately depend on the
local concentrations of the phosphorylated receptor and rele-
vant SH2 domain proteins, and as discussed below in the
context of the cell cycle, the optimal binding motif for an
interaction domain established by in vitro analysis is not in-
variably the one used in vivo. In addition, some physiological
receptor autophosphorylation sites can associate with multiple
SH2 proteins in vivo [63].
SH2 domains tend to bind their cognate peptide ligands
with dissociation constants of approximately 500 nM to
1 WM, and indeed many interaction domains show similar
binding a⁄nities for their ligands, in the order of 0.5^10
WM [64,65]. These a⁄nities appear su⁄cient for speci¢c bind-
ing in vivo, especially when multiple domains are coupled
together to localize interacting proteins to the same place in
the cell and promote multivalent interactions. However, they
also yield fairly high o¡-rates so that the interactions are
dynamic. This is likely important in signaling processes that
must be rapidly turned on and o¡ to accommodate the shift-
ing needs of the cell.
Clearly the speci¢city and a⁄nity with which SH2 domain
proteins interact with activated receptors, and cytoplasmic
docking proteins, can be considerably increased by the pres-
ence of additional interaction domains. Thus, proteins with
two tandem SH2 domains bind cooperatively to bisphos-
phorylated sites [66], and Src family kinases can potentially
interact with their targets through both their SH2 domain and
the covalently linked SH3 domain, which recognizes proline-
rich sequences [67^69].
3. SH2 domains and interaction modules in the evolution of
signaling networks
SH2 domains display features that are characteristic of the
larger family of interaction domains. They are V100 amino
acids long, rather typical of this class of protein modules
which are generally in the 35^150 amino acid range. They
are found in a large number of proteins, which otherwise
have distinct biochemical activities; we presently estimate
there are 111 SH2 domains in the non-redundant set of hu-
man gene products, found in proteins with diverse functions,
including regulation of protein/lipid phosphorylation, phos-
pholipid metabolism, transcriptional regulation, cytoskeletal
organization, and control of Ras-like GTPases (Fig. 1). Based
on this observation, one possible explanation for the wide-
spread use of interaction domains is that they allow for the
rapid evolution of new signaling pathways, by the incorpora-
tion of a novel interaction domain into a pre-existing poly-
peptide. For example, yeast have no functional SH2 domains,
and lack conventional tyrosine kinase activity. However, ty-
rosine kinase activity and the SH2 domain make a coincident
appearance in metazoan organisms (even being found in a
facultative metazoan such as Dictyostelium discoideum)
[70,71] ; one can speculate that tyrosine kinases evolved as a
mechanism to allow communication between cells of increas-
ingly complex organisms, and that the SH2 domain developed
to couple the phosphotyrosine signal to intracellular biochem-
ical pathways. The existence of a phosphotyrosine recognition
module, such as an SH2 domain, then provides a rapid means
of physically linking tyrosine kinases to new signaling path-
ways, by the insertion of an SH2 domain into a pre-existing
enzyme or adaptor protein. The increased complexity of sig-
naling networks in higher organisms may therefore result, in
part, from increasingly numerous interconnections mediated
by interaction domains [72].
In this context, SH2 domains appear optimally structured
to allow their incorporation into a host polypeptide, since
their N- and C-termini are close together in space, and on
the opposite face of the domain from the phosphopeptide-
binding surface. This is a common feature of interaction do-
mains, which presumably facilitates their integration into sur-
face-exposed regions of their host proteins, while preserving
their ligand-binding activity. An exception to this rule in-
volves modules which make homo- or heterotypic interac-
tions, such as SAM domains, that involve their N- and
C-termini. These domains are usually found at the ends of
signaling proteins, presumably because an internal location
would sterically block their ability to self-associate [46].
4. SH2 domains show £exible biochemical properties and
diverse biological functions
A feature of SH2 domains noted above is their ability to act
in synergy with other interaction modules, and signaling pro-
teins commonly possess multiple protein and phospholipid
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Fig. 1. The modular nature of SH2-containing signaling proteins. A comparison of the modular protein domain composition and positional
organization of the non-redundant human SH2 domain-containing proteins identi¢ed by SMART (http://smart.embl-heidelberg.de/). Additional
information on individual domains can be found at http://www.mshri.on.ca/pawson/research1.html and http://smart.embl-heidelberg.de/.
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interaction domains within the same polypeptide chain. This
is evident for SH2/SH3 adaptors, such as Grb2, Nck and Crk
family members, each of which possesses a single SH2 domain
and one to three SH3 domains, and can thereby link a single
phosphotyrosine site to multiple intracellular targets with pro-
line-rich SH3-binding sequences [2,73,74]. Interestingly, Grb2
can potentially regulate both the MAP kinase and PI 3P-ki-
nase pathways, through its ability to engage both the Ras
guanine nucleotide exchange factor Sos [75,76], and the
Gab1/Gab2 docking proteins, which in turn are substrates
for phosphorylation and subsequent recruitment of PI 3P-ki-
nase [77^81]. Thus Grb2 may coordinate signals involved in
growth, di¡erentiation and survival. In contrast, the SH3 do-
mains of Nck recruit proteins involved in cytoskeletal reor-
ganization, such as the PAK serine/threonine kinase, the
N-WASP protein that controls actin polymerization through
an association with the Arp2/3 complex, and WASP-interact-
ing protein (WIP) [82,83]. Thus SH2/SH3 adaptors potentially
function to nucleate signaling complexes containing multiple
proteins involved in a speci¢c aspect of cellular regulation.
Mutations of the Grb2 and Nck genes in both invertebrates
and vertebrates support these biochemical observations. For
example, in Drosophila the Nck gene (termed Dock) is re-
quired for the targeting of speci¢c photoreceptor axons [84],
while in mammalian cells, mutation of both Nck genes abro-
gates the ability of the Tir protein of enteropathogenic Esche-
richia coli (EPEC) to recruit N-WASP and the Arp2/3 com-
plex to the site of bacterial attachment, and thus blocks the
massive reorganization of the actin cytoskeleton normally elic-
ited by binding the phosphorylated EPEC Tir polypeptide to
the Nck SH2 domain [85].
Consistent with this multifaceted role, gene targeting experi-
ments in the mouse have indicated that Grb2 has numerous
biological activities. By analyzing various combinations of
wild-type, hypomorphic and null Grb2 alleles, we have found
that Grb2 is required for endoderm formation in the early
mouse embryo, and thus for development of the blastocyst,
for epiblast formation, for chorio-allantoic fusion and orga-
nization of the spongiotrophoblast layer of the placenta, for
the survival of a subset of migrating neural crest cells, and
therefore for proper formation of the branchial arches, for
closure of the palate, and for negative selection in T cells
[86^88]. These results indicate that a single signaling protein,
and presumably the core Ras-MAP kinase pathway that it
controls, is put to a wide variety of uses at various stages of
embryonic development and postnatal life. The intriguing is-
sue, then, is not so much the organization of individual path-
ways (important as this is), but the identi¢cation of modula-
tory proteins that may shape an individual cell’s response to a
common signaling pathway. Such proteins could be adaptors
or sca¡olding proteins, positive or negative regulators, or pre-
existing transcription factors.
A ¢nal feature of SH2 domains is worth emphasizing,
namely their apparent £exibility. This is demonstrated by
the SH2 domain of the SH2D1A protein (also termed SAP
or DSHP). The SH2D1A protein is comprised almost entirely
of a single SH2 domain, which is mutated in X-linked lym-
phoproliferative disease (XLP), a fatal disorder typi¢ed by an
aberrant T cell response to infection with Epstein^Barr virus
[89^91]. The SH2 domain of SH2D1A is unusual in the sense
that it can bind not only a phosphotyrosine residue and more
C-terminal amino acids, but also engages at least two residues
N-terminal to the phosphotyrosine [92,93]. In this sense,
SH2D1A-binding motifs, such as that found in the C-terminal
tail of the SLAM/CD150 T cell receptor, can be viewed as
having three ‘prongs’ (N-terminal residues, the phosphotyro-
sine and C-terminal residues) that engage the SH2 domain, as
opposed to a conventional SH2 domain-binding motif with
two ‘prongs’. Intriguingly, as a consequence of this increased
binding surface, the SH2D1A SH2 domain can bind the rel-
evant tyrosine-based motif even in its unphosphorylated form,
although phosphorylation of the tyrosine increases binding by
about 5-fold [89,93]. A distinct example is provided by the
mammalian Crk SH2 domain, which has a unique proline-
rich insert in the DE loop which can bind directly to the
Abl SH3 domain [94]. Structural analysis has revealed that
this loop in the SH2 domain does indeed adopt a polyproline
type II helix, which engages the SH3 domain (L. Donaldson,
T. Pawson, L. Kay, J. Forman-Kay, unpublished results).
Thus even in the highly conserved SH2 domain family, there
is su⁄cient structural £exibility to bind either phosphorylated
or non-phosphorylated motifs at the same surface, or an SH3
domain at a di¡erent site.
5. A family of £exible PTB domains
This inherent £exibility of interaction domains is especially
evident for PTB domains, originally characterized through
their ability to recognize phosphorylated Asn-Pro-X-Tyr
L-turn motifs, such as those found in the RTKs for nerve
growth factor (Trk), insulin or epidermal growth factor [95^
97]. The PTB domains of sca¡olding proteins such as Shc,
FRS2 or IRS-1 bind autophosphorylated receptors, position-
ing these proteins for multisite phosphorylation and subse-
quent binding of SH2 domain targets such as Grb2 (for Shc
and FRS2) or PI 3P-kinase (for IRS-1) [98^100]. Interestingly,
the ability of these proteins to associate with activated recep-
tors also appears dependent on their recruitment to the plas-
ma membrane. This is achieved in di¡erent ways ^ the PTB
domain of Shc binds PI-4,5-P2 in addition to phosphopeptide,
FRS2 is myristilated at its N-terminal glycine, and IRS-1 has
a PH domain N-terminal to the PTB domain with the poten-
tial to bind phosphoinositides [99,101,102]. The PTB domain
of FRS2, however, also binds a non-phosphorylated peptide
ligand found in the juxtamembrane region of the FGF recep-
tor, and structural analysis has revealed that this makes a
much more extensive and quite di¡erent interaction with the
PTB domain from that exhibited by Asn-Pro-X-pTyr motifs
[103,104]. Thus a single PTB domain can bind RTKs using
two di¡erent binding modes, one phospho-dependent and the
other phospho-independent. Furthermore, it is now evident
that PTB domains on proteins such as Numb and X11, which
function in the control of asymmetric cell division and traf-
¢cking respectively, bind Asn-X-X-Tyr/Phe L-turn motifs, but
in a fashion that is independent of phosphorylation [105^107].
Furthermore Numb is able to bind unrelated peptide motifs
that adopt di¡erent conformations [108]. As with the
SH2D1A SH2 domain, the additional binding energy forfeited
by the absence of the phosphotyrosine is provided by a more
extensive interface with the unphosphorylated peptide. Thus
PTB domains may have originally evolved to mediate phos-
pho-independent signaling events, involved in processes such
as cell polarity and protein tra⁄cking, and subsequently have
acquired a capacity to recognize phosphotyrosine motifs and
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contribute to tyrosine kinase signaling. Intriguingly, although
they show no obvious sequence relationship to PTB domains,
PH domains (which recognize phosphoinositides) and EVH1
domains (which bind proline-rich sequences) have the same
fold as PTB domains, suggesting that this structure represents
a £exible sca¡old which can be adapted to mediate a wide
range of protein^protein and protein^phospholipid interac-
tions [109^112].
6. Phosphoserine/threonine recognition domains ^ a familiar
theme
A growing family of interaction domains have been identi-
¢ed as binding phosphoserine/threonine-containing motifs,
suggesting that protein phosphorylation is a rather general
way of regulating protein^protein interactions [11]. This was
¢rst recognized in the context of 14-3-3 proteins, which binds
motifs such as Arg-Ser-X-pSer-X-Pro [113,114], and has more
recently been described for FHA domains, which are found in
proteins that regulate the DNA damage response (i.e. Rad53,
Chk2), gene expression (Forkhead proteins) and protein traf-
¢cking (kinesins) [115,116]. FHA domains bind preferentially
to phosphothreonine motifs, and recognize the +3 residue rel-
ative to the phosphothreonine in a fashion that di¡ers from
one FHA domain to another and may impart biological spec-
i¢city. Intriguingly, although the structural mechanisms are
quite di¡erent, this is reminiscent of SH2 domains, which
generally bind phosphotyrosine and show a strong selectivity
for the +3 residue. Interestingly, the FHA domain fold is very
similar to that of MH2 domains, found at the C-terminus of
Smad proteins, the targets of TGF L-receptor serine/threonine
kinases [115,117]. Recent work has suggested that autophos-
phorylation of serine residues within the juxtamembrane re-
gion of the type I TGF L-receptor may provide a docking site
which is recognized by the MH2 domain of regulatory (R-)
Smad proteins, positioning the R-Smad for C-terminal serine
phosphorylation by the activated receptor [118]. This in turn
leads to its oligomerization with the common Smad (Smad4),
and subsequent relocalization to the nucleus where the Smad
complex participates in the regulation of gene expression.
There are conceptual similarities between this mode of regu-
lated receptor^target interactions, and that revealed by struc-
tural analysis of the autoinhibited EphB2 RTK, a representa-
tive of the largest family of mammalian RTKs [119] (Fig. 2).
In the inactive state, the juxtamembrane region of EphB2 is
ordered, and folds against the kinase domain, primarily mak-
ing contact with the small lobe. Two juxtamembrane tyrosine
residues which are subject to autophosphorylation upon
EphB2 activation are inserted into hydrophobic pockets,
formed by residues from the juxtamembrane region itself as
well as the catalytic domain. In the autoinhibited state, the
juxtamembrane region appears to repress kinase activity by
creating a kink in the KC-helix of the small lobe of the kinase
domain; this movement is transmitted to the ATP-binding
site, so that although ATP can bind, the phosphates are not
productively positioned for phosphotransfer. In addition, the
juxtamembrane region may inhibit the movement of the acti-
vation segment of the kinase domain into an active conforma-
tion. EphB2 activation leads to autophosphorylation of the
juxtamembrane tyrosines, which we predict are therefore ex-
pelled from their pockets as a result of electrostatic repulsion
and steric clash. We speculate that this leads to the disorder-
ing of the juxtamembrane region, freeing the kinase domain to
snap into an active state; coincidentally the juxtamembrane
phosphotyrosines are exposed for potential interactions with
SH2 domain proteins. This model is remarkably similar to
that proposed for the activation of the type I TGF L-receptor,
and the subsequent interaction of its phosphorylated juxta-
membrane region with R-Smad targets [118]. The principal
Fig. 2. Regulation of receptors by phosphorylation of juxtamem-
brane residues. A: The EphB2 receptor tyrosine kinase is held in an
inactive conformation by an interaction between the juxtamembrane
segment and residues of the small lobe of the kinase. Autophos-
phorylation of dual tyrosine residues in the juxtamembrane segment
results in a structural reorganization that allows ATP to produc-
tively bind in the kinase active site and allows the activation seg-
ment to adopt a production conformation, resulting in an active ki-
nase. Furthermore, the phosphorylated tyrosine residues can
subsequently act as binding sites for SH2 domain-containing pro-
teins. B: In a similar manner, the TGF L-receptor is held in its in-
active conformation by FKBP12 binding to the juxtamembrane seg-
ment. Autophosphorylation of multiple serine and threonine
residues in the juxtamembrane segment releases inhibition. These
phosphorylated sites in turn act to recruit Smad2, which is itself
phosphorylated, allowing Smad2 to bind to Smad4. The Smad2/
Smad4 complex translocates to the nucleus where it acts to promote
transcription.
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di¡erence involves the observation that the autoinhibited state
of the TGF L-receptor involves an accessory protein,
FKBP12, which is required for the folding of the juxtamem-
brane region and occlusion of the ATP-binding site.
7. The use of phospho-dependent protein interactions to
regulate complex events in the cell cycle
Recent data have suggested that one important function of
both tyrosine and serine/threonine phosphorylation is to cre-
ate binding sites for E3 protein ubiquitin ligases, proteins (or
protein complexes) that mediate transfer of ubiquitin from an
E2 enzyme to a speci¢c substrate, which is then recognized
by cellular machines involved in proteolysis or endocytosis.
c-Cbl, for example, has a variant SH2 domain at its N-termi-
nus, which recognizes sites on activated RTKs, followed by a
RING-H2 domain that binds E2 ubiquitin ligases [120^122].
Thus c-Cbl acts in essence as an adaptor to recruit an E2
ubiquitin ligase to an activated RTK, and thereby promote
ubiquitination and downregulation of the receptor.
SCF complexes are multi-subunit E3 protein ubiquitin li-
gases, comprised of a sca¡olding protein (Cullin), which in-
teracts with an E2 enzyme, a RING-H2 protein, and an adap-
tor, Skp1 [123]. Skp1 in turn recognizes the N-terminal F-box
of a targeting subunit which binds through a variable C-ter-
minal domain, often composed of WD40 repeats or leucine-
rich repeats, to the substrate for ubiquitination [124^126]. The
binding of the substrate to the C-terminus of the F-box pro-
tein is frequently dependent on the phosphorylation of the
target on serine or threonine, and the ubiquitination and sub-
sequent degradation of such a protein is therefore regulated
by its serine/threonine phosphorylation [127]. We have re-
cently analyzed the phospho-dependent degradation of the
Sic1 cyclin-dependent kinase (CDK) inhibitor in the yeast
Saccharomyces cerevisiae, using a combination of biochem-
ical and genetic tools [128]. Sic1 is a speci¢c inhibitor of the
S phase CDK, composed of the Cdc28 kinase associated with
Clb-type cyclins [129]. In the G1 phase of the yeast cell cycle,
the G1 CDK (Cdc28 associated with Cln-type cyclins) phos-
phorylates Sic1 at nine Ser/Thr-Pro motifs, and the phosphor-
ylated form of Sic1 is then recognized by the WD40 repeat
domain of an F-box protein termed Cdc4, which is part of a
larger SCF E3 ubiquitin ligase complex [124,127,130] (Fig. 3).
The recruitment of phospho-Sic1 to the SCFCdc4 complex
leads to its ubiquitination and destruction, and this relieves
the inhibition of the S phase Cdc28-Clb CDK, allowing the
initiation of DNA replication. Thus Sic1 is the key substrate
of the G1 CDK, because Sic1 phosphorylation, and conse-
quent recognition by the Cdc4 F-box protein, acts as a switch
to promote transition for the G1 to the S phase of the cell
cycle. A mutant form of Sic1 that lacks all Cdc28-Cln phos-
phorylation sites is stable, and therefore toxic because cells
cannot replicate their DNA [131].
In trying to understand how Sic1 serine/threonine phos-
phorylation mediates its recognition by the Cdc4 WD40 do-
main, we found that no single Sic1 phosphorylation site is
su⁄cient to mediate stable Cdc4 binding, Sic1 ubiquitination,
or progression into S phase [128]. Indeed, Sic1 must be phos-
phorylated on at least six sites to associate with Cdc4 and
allow passage through G1. Although the physiological Sic1
phosphorylation sites do not bind Cdc4 with high a⁄nity,
we observed that phosphopeptides from human cyclin E1 or
yeast Gcn4 (a transcriptional regulator that is also targeted by
the SCFCdc4 complex) bound to the Cdc4 WD40 domain with
a Kd of V1 WM, and a Hill coe⁄cient of 1, suggestive of a
single class of binding site. Analysis of peptide SPOTS arrays
yielded a consensus-binding motif for the Cdc4 WD40 repeats
of Ile/Leu-Ile/Leu/Pro-pThr-Pro, with a selection against basic
residues at the +2 to +5 positions. These results explain why
no single Sic1 phosphorylation site binds well to Cdc4, since
these sites are all sub-optimal with respect to the preferred
consensus. We found that insertion of the optimal recognition
motif into a Sic1 variant lacking all endogenous phosphory-
lation sites was su⁄cient for stable binding to Cdc4, and for
elimination of the Sic1 CDK inhibitor. However, this variant
form of Sic1 was not able to fully replace the endogenous
protein, as it was degraded prematurely, leading to precocious
entry into S phase, and genome instability likely due to pre-
mature ¢ring of DNA replication origins. These and related
results have suggested that the Cdc4 F-box protein has a
single phosphothreonine-binding pocket, containing three es-
sential arginine residues, which binds in equilibrium to multi-
ple low a⁄nity sites on Sic1. This requirement for multisite
phosphorylation of Sic1 establishes a threshold of G1 CDK
activity which must be surpassed for stable Cdc4 binding, and
thus for Sic1 degradation and activation of the S phase CDK.
Thus, Sic1 multisite phosphorylation and consequent Cdc4
recognition in essence provide a timing device for transit
through the G1 phase of the cell cycle, and guard against
adventitious entry into S phase in response to low level
Fig. 3. Multisite phosphorylation of the CDK inhibitor Sic1 creates
an ultrasensitive biological switch for the onset of DNA replication.
Phosphorylation of Sic1 by the Cln1/2-Cdc28 cyclin-dependent ki-
nase is required for the productive interaction of Sic1 with the
WD40 region of the Cdc4 F-box protein. Binding of Sic1 to Cdc4
results in ubiquitination of Sic1 by the SCFCdc4 E3 ubiquitin protein
ligase complex and subsequent degradation of Sic1. The requirement
for multisite phosphorylation results in a sigmoidal stimulus^re-
sponse curve, e¡ectively creating an ultrasensitive biological switch.
By contrast, the interaction between the transcription factor Gcn4
and Cdc4 is dependent upon a single phosphorylation event result-
ing in a graded stimulus^response curve that obeys Michaelian ki-
netics (inset).
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Cdc28-Cln activity, as well as providing for a switch-like deg-
radation of Sic1 once the appropriate level of G1 CDK ac-
tivity has been reached (Fig. 3).
These results show that the phospho-dependent recognition
of regulatory proteins by the SCF E3 complex is critical for
cell cycle progression, and identify a phosphothreonine-bind-
ing site in the WD40 repeat domain of the Cdc4 protein.
More importantly, they demonstrate that this simple binary
interaction can be used to monitor levels of G1 CDK activity,
and thus to elicit an ultrasensitive response to Cdc28-Cln ki-
nase activity that ensures an orderly and timely transition into
the S phase of the cell cycle.
8. Summary
Interaction domains are used to regulate many aspects of
cellular function. We are starting to gain a detailed under-
standing of how individual interaction domains promote the
formation of signaling complexes, and to draw out general
rules that can be applied to many types of protein^protein
and protein^phospholipid interactions [21]. A challenge for
the future is to understand how interaction domains cooper-
ate to establish the complex signaling networks that control
events as fundamental and as complex as passage through the
cell cycle, or organization of the neuronal or immunological
synapse.
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